The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT outcomes between the two diseases have never been formally compared. Among all patients with a diagnosis of AL or MM who received auto-SCT as primary therapy at the Mayo Clinic, Rochester, there were higher CR rates (40% versus 29%, Po0.0001) in the AL group. The respective median OS for the AL and MM patients was 113 and 59.5 months, respectively, Po0.0001. Among patients achieving CR, MM patients had a fivefold risk of death as compared with AL patients. Although auto-SCT cannot be offered to all patients with either AL or MM, it appears that for those well enough to be chosen for the procedure, greater benefit is derived among the AL patients. This difference in survival is most notable among those patients who achieve CR, suggesting very different plasma cell biology between the two diseases.
INTRODUCTION
Both multiple myeloma (MM) and Ig light-chain amyloidosis (AL) are plasma cell disorders. [1] [2] [3] The diseases differ from each other in terms of 'tumor burden,' tumor biology and the impact the clonal Ig has on other vital organ systems aside from the hematopoietic system. Currently, treatment strategies for the two disorders are similar in terms of chemotherapeutic options as there are no approved drugs that have been shown to directly remove amyloid from tissues. 4, 5 However, the therapeutic window of chemotherapy for patients with AL is narrower than for MM, resulting in more TRM and mortality. [6] [7] [8] Despite this, OS for both conditions has improved dramatically over the past decade in part due to the use of highdose melphalan with auto-SCT, to new drugs like thalidomide, lenalidomide and bortezomib. 9, 10 The greatest improvements have occurred in younger patients, who are candidates for auto-SCT. 11, 12 Patients with AL undergoing auto-SCT are highly selected. 13 Since the twenty-first century, the expected median OS from auto-SCT for both MM and AL patients is approximately 5 years. The respective median unmaintained PFS rates are approximately 22 and 31 months, respectively. [14] [15] [16] [17] Many authors have tied complete hematologic response rates to better PFS and OS in both diseases, but rates of CR after auto-SCT appear to be comparable in patients with AL and MM despite the fact that the former group typically does not receive induction therapy before auto-SCT.
Reports from our center and elsewhere would suggest that among patients with AL and MM, who are fit enough to be selected to undergo auto-SCT, patients with AL appear to do as well if not better than patients with MM, but a formal analysis has never be performed. Using our prospectively maintained AL and MM auto-SCT databases, we set out to test our hypothesis that patients with AL who undergo auto-SCT-especially those who achieve CR-fare better than MM patients receiving the same therapy.
PATIENTS AND METHODS
Approval for this study was obtained from the Mayo Clinic Institutional Review Board. All patients with a diagnosis of AL or MM who received auto-SCT at the Mayo Clinic, Rochester, between June 1996 and January 2011 were compiled from two prospectively maintained databases (M.A.G.) to compare outcomes. During the study interval, a total of 2245 patients with AL were seen at the Mayo Clinic, Rochester, within 1 year of their diagnosis; 454 (20.2%) underwent auto-SCT-415 (18.4%) within 12 months of diagnosis. During that same interval, a total of 3160 patients with active MM were also seen within 1 year of diagnosis, and 1116 (35.7%) had auto-SCT at our institution-790 (25%) within a year of diagnosis. All patients with AL had biopsy-proven amyloid disease by Congo red stain. The diagnosis of MM was made using conventional criteria. 1 All but 97 patients were conditioned with single-agent high-dose melphalan; 81 MM patients and 16 AL patients received melphalan and TBI conditioning. Standard supportive care measures were employed, and maintenance therapy was not part of standard clinical practice for either group. All patients were classified as CR, very good PR (VGPR), PR or no response. Response for MM patients was coded in accordance with the international uniform response criteria for MM. 18, 19 Hematologic response criteria for AL patients were defined according to the consensus opinion from the Tenth International Symposium on Amyloid and Amyloidosis, but also included the recent consensus updates that allow for the VGPR category, which is defined as a reduction in the involved Ig free light-chain to 40 mg/L or less. 20, 21 Statistical analysis Differences between nominal groups were compared using Fisher's exact and Kruskall-Wallace tests. All P-values were two sided. Survival and PFS were calculated from the time of transplant using the Kaplan-Meier method, and differences between survival outcomes were calculated by log-rank tests. Patients were censored at the time of last follow-up for both survival and PFS estimates. Death due to any cause was considered a progression event. Median follow-up of surviving patients was 59.5 months. Risk ratios were calculated using Cox proportional hazards, and risk was reported per unit value unless otherwise stated. For multivariate analyses, Cox regression modeling was used, adding in factors that were significant in the univariate model in a stepwise manner. Separate models were also performed to determine how acquisition of CR, non-diseasespecific parameters (age, time period of auto-SCT, number of prior regimens, time to auto-SCT from diagnosis), and disease-specific parameters (BM plasmacytosis, creatinine, b-2 microglobulin, lactate dehyrogenase (LDH), C-reactive protein (CRP), albumin, serum M spike, urine total protein) affected outcomes. All statistical analyses were performed using JMP (SAS, Cary, NC, USA) software.
RESULTS
The pre-transplant characteristics of the 454 AL and 1116 MM patients who received auto-SCT are shown in Table 1 . The age and gender mix of both populations were comparable, but there were significant differences between the two populations in terms of number of prior regimens (0 versus 1), time to auto-SCT (4.0 versus 7.2 months), intensity of conditioning regimen (non-attenuated in 69.4% versus 89.1%), serum creatinine (1.1 versus 1.0 mg/dL), albumin (2.6 versus 3.50 g/dL), C-reactive protein (0.4 versus 0.6 mg/dL), LDH (196 versus 182 U/L), BM plasmacytosis (6% versus 9%), serum M spike (0.1 versus 0.8 mg/dL) and urine total protein (3.7 versus 0.09 g/24 h).
As shown in Table 2 , 100-day TRM differed between the AL and MM groups (8.8% versus 1.4%, Po0.0001, respectively). Hematologic response rates were also significantly different, with higher overall hematologic response (79.5% versus 90.9%, Po0.0001) and VGPR (13.4% versus 25.4%, Po0.0001) in the MM group, but higher CR rates (40.1% versus 29.4%, Po0.0001) in the AL group. Despite the higher TRM in the AL group, which resulted in an inferior 1 year OS, the estimated median OS rates for the AL and MM groups were 113.3 and 59.5 months, Po0.0001 (Figure 1a) , respectively, and the 5-year OS rates were 66.2% and 49.4%. Because time to transplant was so different for the AL and MM groups with only 91.4% of AL and 71% of MM patients transplanted within 12 months of diagnosis, Kaplan-Meier estimates were generated excluding the 385 patients who had auto-SCT 12 months after diagnosis ( Figure 1b) . Once again, all survival measures favored the AL group ( Table 2 ). The survival advantage persisted when a landmark analysis was done including only those 1158 patients transplanted within 12 months of diagnosis who also survived 100 days post-auto-SCT ( Figure 1c ).
Separate univariate analyses were performed to identify factors that influenced OS for the entire cohort and for that subset of patients transplanted within 12 months of diagnosis (Table 3) . In both analyses, the following factors adversely affected OS: no attainment of CR; MM diagnosis; earlier time period of auto-SCT (1996-2002 versus 2003-2006 versus 2007-2010) ; BM plasmacytosis at transplant greater than 10%; lower dose intensity of conditioning regimen; higher b-2 microglobulin; and higher proliferative rate of plasma cells (plasma cell labeling index (PCLI)). In the 'all patient' group, the following other factors were also significantly associated with OS: longer time between diagnosis and auto-SCT; older age; male gender; greater than 1 prior regimen; lower urinary total protein; and higher creatinine, LDH or serum M spike.
A multivariate analysis including only those patients transplanted within 12 months of diagnosis was performed. Those variables that had a significant adverse effect on OS included: lack of CR, attenuated melphalan conditioning, MM diagnosis, BM plasmacytosis, high LDH, high plasma cell labeling index and earlier era of auto-SCT. To test the study's underlying hypothesis that patients with AL achieving CR have better outcomes than MM patients achieving CR, a second multivariable analysis was done that included only the 420 patients who achieved CR. With 137 deaths, the only factors that increased a patient's risk of death were a diagnosis of myeloma, attenuated dose of melphalan conditioning and higher BM plasmacytosis ( Table 4) . The risk ratio of death for a diagnosis of MM as compared with AL was 5.1 (3.3-8.3).
Kaplan-Meier curves were generated to further study the differential role of response between patients with AL and MM including only those patients undergoing auto-SCT within 12 months of their diagnosis and using a 100-day landmark analysis for OS. AL patients achieving a hematologic CR had superior OS as compared with their MM counterparts with respective median OS of not reached and 84 months, Po0.0001, and 5-year OS rates of 90.5 and 61.6%, Po0.0001 (Figure 2a ). The uncorrected risk ratio for death was 4.2 (95% CI: 2.7-6.7, Po0.0001) among the MM patients. Similarly, AL patients achieving a hematologic VGPR also had better outcomes than their MM counterparts with 5-year OS rates of 74.4% and 59.4%, respectively (Figure 2b) , with a risk ratio of death of 2.0 (95% CI: 1.2-3.5, P ¼ 0.004). However, when the patient populations were restricted to only those who achieved Auto-SCT in AL versus MM A Dispenzieri et al hematologic PR, 5-year OS rates were comparable at 56.0% and 52.5%, respectively, P ¼ NS (Figure 2c ). Restricting the analyses to those patients achieving less than a PR revealed a trend toward better outcomes among the MM patients 35.3% versus 41.4%, P ¼ NS (Figure 2d ).
DISCUSSION
The current study carries four important novel messages. First, the selection of patients for auto-SCT is more stringent among AL patients than among MM patients, with fewer than one in five AL patients moving to auto-SCT versus one in four MM patients proceeding to early auto-SCT at our institution. Second, even in a tertiary center that specializes in the care of AL, the TRM for auto-SCT is nearly fivefold higher for AL patients as compared with MM patients. Third, although overall response rates and VGPR rates are higher among the MM patients, CR rates are higher in patients with AL. Fourth, long-term OS of patients with AL undergoing auto-SCT is better than that of patients with MM undergoing the same procedure, with the most dramatic benefits seen among those patients achieving CR. These data highlight both the benefit of transplant among AL patients healthy enough to undergo auto-SCT and the differences between these two disease entities, most notably in terms of their tumor biology. This latter point is an indirect measurement, but as demonstrated in the multivariable analysis, when all external factors like timing of transplant, dose of melphalan and number of prior regimens are corrected for, diagnosis and attainment of CR were the most powerful predictors of outcome. Despite the fact that patients with AL can have severely impaired organ function, patients with AL on the whole fared better than MM patients. This advantage was enjoyed by the 53% of AL patients who achieved a VGPR or better, with a fourfold better OS for the AL patients achieving CR as compared with MM patients and a twofold better OS for the AL patients achieving VGPR again as compared with MM patients. Even without maintenance therapy, the KaplanMeier estimate of a 10-year survivorship for AL patients achieving CR was 75% even without maintenance therapy.
The take-home message of this study should not be that more patients with AL should receive auto-SCT since even in this highly selected patient population TRM was not trivial. Our practice of bringing only about 20% of our AL patients to transplant differs from the practice at other institutions, where 45% of patients receive auto-SCT. 22 At our institution, over time, the stringency of selecting AL patients for auto-SCT has fluctuated, moving from stringent to less stringent (but with attenuated melphalan doses), to more stringent, with our highest rates of auto-SCT for AL patients from 2001-2006 at 25%. Our practices have been influenced by data. The only method for bringing more, that is, sicker, patients to auto-SCT is to attenuate the conditioning dose of melphalan. The current data as well as prior reports demonstrate that although reducing conditioning doses of melphalan allows for sicker patients to make it through auto-SCT, response rates and OS rates suffer. 14, 23, 24 Using standarddose melphalan conditioning is also not an option for the sickest patients because patients with more severe cardiac involvement have TRM rates of 28-43%. 8, 25 In addition, the one randomized trial that compared melphalan and dexamethasone to auto-SCT did not show superiority of auto-SCT over conventional chemotherapy in part due to high rates of treatment mortality and in part due to attenuated conditioning doses of melphalan in the sicker patients. 24 So where to go from here? Several approaches are being tried for AL patients, including non-transplant options like melphalan and dexamethasone, bortezomib-based treatments and immune modulator-based regimens. 2, [26] [27] [28] [29] [30] [31] [32] There have been two phase 2 trials that employ risk-adapted melphalan conditioning followed by post-auto-SCT consolidation with either thalidomide and dexamethasone or bortezomib and dexamethasone. 33, 34 Although these authors have observed upgrading in response quality with this approach, to date there is no information about how this approach affects OS. There are also anecdotal reports of treating patients with non-transplant chemotherapy in order to improve the AL patients' performance status and then using auto-SCT as a consolidative therapy. 35 These data bring the question of whether all patients with AL should be treated until they achieve CR to the forefront. Because biology often trumps treatment, and the functional status of a patient can morph a potentially effective therapy into a fatal therapy as has been repeatedly been shown in the earliest AL transplantation studies 8, 25 and in several myeloma studies, most notably those treating elderly MM patients. 36, 37 The decision to treat patients until they reach a VGPR or CR 21 must be made balancing the toxicity of therapy against the urgency of needing an organ response.
Studies addressing differences between the biology of AL plasma cells and MM plasma cells are limited. Girnius et al. 38 addressed a slightly different question when they reported on their experience transplanting 16 patients with AL and concurrent MM. They found that the CR rate was 25% and the OS for these patients was 54 months. In contrast, the average patient with AL has a lower tumor burden and plasma cells that are less proliferative. Gene expression profiling would suggest that plasma cells from patients with AL are more like MGUS plasma cell (PC). 39 The chromosomal abnormalities found in AL are highly weighted toward what would be deemed favorable among MM patients, 40, 41 with a paucity of high-risk cytogenetic abnormalities like t(4;14), t(14;16), deletion 17p and increased copy numbers of 1q21. These favorable genetics may in part explain the superior outcomes enjoyed by the majority of AL patients in this series. Because FISH was not available for the majority of the AL patients, we could not specifically prove this point.
Our study leaves investigators and readers with as many questions as answers. Further study is required to understand the biology of the plasma cells of patients with AL, but even without Auto-SCT in AL versus MM A Dispenzieri et al that additional study, the current manuscript provides empiric information about the differences between AL and MM. CR in AL means more than it means in MM, perhaps in part due to the inadequacy of the present day definitions of CR. The standard approach of induction, followed by auto-SCT, followed by consideration of maintenance therapy that is employed in patients with MM is not necessarily appropriate in the majority of patients with AL destined for auto-SCT. Further clinical directions should focus on how one can improve upon outcomes for the 38% of patients with AL who survive 100-days post auto-SCT, but achieve a PR or less. 
CONFLICT OF INTEREST
AD
